Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid and BMS-275291 in Hormone Refractory Prostate Cancer
NCT00039104Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2002
- Primary completion
- Jan 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rebimastat in prostate cancer (PCa) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Confirmed response (PSA decline of greater than 50% confirmed at least four weeks apart) up to 2 years. Started Apr 2002; status: completed.
02
Drugs
rebimastat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00039104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00039104.